Evidence map›Paper›PMID 39851576›Full record

ReviewCells2025

Detection of Cancer Stem Cells from Patient Samples.

Sofia Hakala, Anna Hämäläinen, Sanne Sandelin, Nikolaos Giannareas, Elisa Närvä

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Development of a prognostic model based on m6A readerTranslational cancer research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sofia HakalaInstitute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, Finland.ORCID 0000-0001-9752-0309
Anna HämäläinenInstitute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, Finland.ORCID 0009-0008-3372-6082
Sanne SandelinInstitute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, Finland.ORCID 0009-0000-1261-6812
Nikolaos GiannareasInstitute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, Finland.ORCID 0000-0002-3047-6072
Elisa NärväInstitute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, Finland.ORCID 0000-0003-0517-9436

Funding

Drug Research Doctoral Programme (DRDP) NSFinnish Cultural Foundation NSiCAN Digital Precision Cancer Medicine Flagship NSImmuDocs NSJane and Aatos Erkko Foundation NSSvenska Kulturfonden NSTurku Doctoral Programme of Molecular Medicine NS
6 · The paper itself

Abstract

The existence of cancer stem cells (CSCs) in various tumors has become increasingly clear in addition to their prominent role in therapy resistance, metastasis, and recurrence. For early diagnosis, disease progression monitoring, and targeting, there is a high demand for clinical-grade methods for quantitative measurement of CSCs from patient samples. Despite years of active research, standard measurement of CSCs has not yet reached clinical settings, especially in the case of solid tumors. This is because detecting this plastic heterogeneous population of cells is not straightforward. This review summarizes various techniques, highlighting their benefits and limitations in detecting CSCs from patient samples. In addition, methods designed to detect CSCs based on secreted and niche-associated signaling factors are reviewed. Spatial and single-cell methods for analyzing patient tumor tissues and noninvasive techniques such as liquid biopsy and in vivo imaging are discussed. Additionally, methods recently established in laboratories, preclinical studies, and clinical assays are covered. Finally, we discuss the characteristics of an ideal method as we look toward the future.

Indexed as

NeoplasmsNeoplastic Stem CellsAnimalsHumansSingle-Cell Analysiscancer stem cell (CSC)cytometrydiagnosticsimmunoassayimmunohistochemistry (IHC)liquid biopsymedical imagingmultiplexsingle-cell RNA sequencing (scRNA-seq)spatial transcriptomics

Identifiers

PMID39851576
PMCPMC11764358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.